Trovagene Inc (TROV) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Trovagene Inc (Trovagene) is a clinical-stage cancer therapeutics company that focuses on improved cancer care using its technology in tumor genomics. Its lead product, PCM-075, is a polo-like kinase 1 (PLK1) inhibitor that helps treat solid tumor cancers and multiple hematologic malignancies. The companys pipeline products include TROV-052 for the treatment of acute myeloid leukemia; and TROV-053 for the treatment of castration-resistant prostate cancer. Trovagene harnesses its proprietary Precision Cancer Monitoring (PCM) technology to analyze circulating tumor DNA (ctDNA) and clinically actionable markers for the detection and quantitation of oncogene mutations, which enable it to discover patients with possibility to respond to targeted cancer therapies. Trovagene is headquartered in San Diego, California, the US.

Trovagene Inc (TROV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Trovagene Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Trovagene Inc, Medical Devices Deals, 2012 to YTD 2018 10
Trovagene Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Trovagene Inc, Pharmaceuticals & Healthcare, Deal Details 12
Licensing Agreements 12
Trovagene Enters into Licensing Agreement with Nerviano Medical Sciences for PCM-075 12
TrovaGene Enters Into Licensing Agreement With Quest Diagnostics For NPM1 Marker 13
Trovagene Enters Into Licensing Agreement With Duke University And Duke University Health Systems For NPM1 Marker 14
Trovagene Enters Into Licensing Agreement With Genoptix For NPM1 Marker 15
TrovaGene Enters Into Licensing Agreement With Amedeo Avogadro University And Sapienza University 16
Equity Offering 17
Trovagene Raises USD18 Million in Public Offering of Shares 17
Trovagene Inc - Key Competitors 19
Trovagene Inc - Key Employees 20
Trovagene Inc - Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
May 08, 2018: Trovagene Announces First Quarter 2018 Highlights and Financial Results 22
Feb 26, 2018: Trovagene Announces Fourth Quarter and Full-Year 2017 Results 23
Nov 09, 2017: Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results 25
May 10, 2017: Trovagene Announces First Quarter 2017 Company Highlights and Financial Results 27
Corporate Communications 29
Jun 22, 2018: Trovagene Announces Senior Management Change 29
Sep 20, 2017: Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis 30
Jul 10, 2017: Trovagene Regains Compliance with NASDAQ Listing Requirements 31
Apr 13, 2017: Trovagene Announces the Addition of Dr. Sandra Silberman to its Clinical Advisory Board 32
Product News 34
12/21/2017: Trovagene Announces Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075 34
Dec 12, 2017: Trovagene Announces the Launch of NextCollect Urine Collection and DNA Preservation Kit to Research Laboratories and Pharmaceutical Customers 35
11/13/2017: Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia Trial for PCM-075 36
07/27/2017: Trovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia 37
07/06/2017: Trovagene Engages Leading CRO in AML to Conduct Phase 1b/2 Trial of PCM-075 38
06/22/2017: Trovagene Announces Agreement with Global Biopharmaceutical Company to Utilize Trovera ctDNA Tests and Services in Cancer Clinical Trials 39
04/17/2018: Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine 40
04/16/2018: Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML) 41
04/12/2018: Trovagene Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2018 42
03/05/2018: Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial 43
02/06/2018: Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM-075 in Acute Myeloid Leukemia 44
Product Approvals 45
Oct 09, 2017: FDA Grants Orphan Drug Designation to Trovagenes PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML) 45
Jun 27, 2017: Trovagene Announces Submission of Investigational New Drug Application to Initiate Phase 1b/2 Clinical Trial of PCM-075 for Acute Myeloid Leukemia 46
Clinical Trials 47
Feb 13, 2018: Yale Cancer Center and Kansas University Cancer Center now actively screening and enrolling patients in Phase 1b/2 Study of PCM-075 in Acute Myeloid Leukemia (AML) 47
Feb 09, 2018: Trovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium 48
Jan 24, 2018: Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) 50
Dec 14, 2017: Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga for Metastatic Castration-Resistant Prostate Cancer 52
Dec 07, 2017: Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga at San Antonio Breast Cancer Symposium (SABCS) 53
Oct 18, 2017: Trovagenes PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells 54
Aug 21, 2017: Trovagenes PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines 55
Aug 16, 2017: Trovagenes PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy 56
Jul 25, 2017: Greater selectivity for PLK1, potency, oral bioavailability and short half-life underscore PCM-075s potential as safe and effective treatment for solid tumor and hematological malignancies 57
May 25, 2017: Phase 1 Safety Study Supports Planned Development of PCM-075 in AML 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List Of Tables

List of Tables
Trovagene Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Trovagene Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Trovagene Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Trovagene Inc, Medical Devices Deals, 2012 to YTD 2018 10
Trovagene Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Trovagene Enters into Licensing Agreement with Nerviano Medical Sciences for PCM-075 12
TrovaGene Enters Into Licensing Agreement With Quest Diagnostics For NPM1 Marker 13
Trovagene Enters Into Licensing Agreement With Duke University And Duke University Health Systems For NPM1 Marker 14
Trovagene Enters Into Licensing Agreement With Genoptix For NPM1 Marker 15
TrovaGene Enters Into Licensing Agreement With Amedeo Avogadro University And Sapienza University 16
Trovagene Raises USD18 Million in Public Offering of Shares 17
Trovagene Inc, Key Competitors 19
Trovagene Inc, Key Employees 20

List Of Figures

List of Figures
Trovagene Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Trovagene Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Trovagene Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Trovagene Inc, Medical Devices Deals, 2012 to YTD 2018 10

Trovagene Inc (TROV) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Trovagene Inc (Trovagene) is a clinical-stage cancer therapeutics company that focuses on improved cancer care using its technology in tumor genomics. Its lead product, PCM-075, is a polo-like kinase 1

USD 250 View Report

TrovaGene Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

TrovaGene Inc Company Profile is a detailed strategic and analytical report on TrovaGene Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

TrovaGene Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

TrovaGene Inc Company Profile is a detailed strategic and analytical report on TrovaGene Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

Trovagene Inc (TROV) - Product Pipeline Analysis, 2018 Update

Trovagene Inc (Trovagene) is a clinical-stage cancer therapeutics company that focuses on improved cancer care using its technology in tumor genomics. Its lead product, PCM-075, is a polo-like kinase 1

USD 750 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available